Reality Check

MMIT Reality Check on Acute Lymphoblastic Leukemia (Jun 2019)

June 28, 2019

According to our recent payer coverage analysis for acute lymphoblastic leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for acute lymphoblastic leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for acute lymphoblastic leukemia treatments shows that under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Kymriah is the first FDA-approved CAR-T cell therapy indicated for patients up to 25 years of age with relapsed or refractory B-cell ALL. Most payers list Kymriah as a drug that needs prior authorization, because a number of restrictions exist when using this medication.

MMIT Reality Check on Hemophilia A or B With Inhibitors (Jun 2019)

June 21, 2019

According to our recent payer coverage analysis for hemophilia A or B with inhibitors treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for hemophilia A or B with inhibitors treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia A or B with inhibitors treatments shows that under the pharmacy benefit, about 45% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Hemophilia treatments have focused on procoagulants, but researchers now are looking into therapies that target natural anticoagulants.

MMIT Reality Check on Ankylosing Spondylitis (Jun 2019)

June 14, 2019

According to our recent payer coverage analysis for ankylosing spondylitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for ankylosing spondylitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ankylosing spondylitis treatments shows that under the pharmacy benefit, about 68% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In April 2019, the FDA approved Samsung Bioepis Co., Ltd.’s Eticovo (etanercept-ykro) for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psorasis in people at least four years old, psoriatic arthritis and polyarticular juvenile idiopathic arthritis in children at least two years old.

MMIT Reality Check on Urothelial/Bladder Cancer (Jun 2019)

June 7, 2019

According to our recent payer coverage analysis for urothelial/bladder cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for urothelial/bladder cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for urothelial/bladder cancer treatments shows that under the pharmacy benefit, about 24% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In April 2019, the FDA gave accelerated approval to the Janssen Pharmaceutical Companies of Johnson & Johnson’s Balversa (erdafitinib).

MMIT Reality Check on Endometriosis (May 2019)

May 31, 2019

According to our recent payer coverage analysis for endometriosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for endometriosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for endometriosis treatments shows that under the pharmacy benefit, around 46% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: ObsEva SA announced in May 2019 that they initiated the Phase III development program of linzagolix, a novel, orally administered gonadotropin-releasing hormone receptor antagonist, to treat women with endometriosis-associated pain.

MMIT Reality Check on Pain Narcotic Opioid (May 2019)

May 24, 2019

According to our recent payer coverage analysis for pain narcotic opioid treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for pain narcotic opioid treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for pain narcotic opioid treatments shows that under the pharmacy benefit, around 43% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Many brand name products (Xtampza ER, Oxaydo) continue to enter this market despite the numerous generics. Via AIS Health.